Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Danazol Taj PharmaCeuticals

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Danazol Manufacturers in India Suppliers Danazol Exporters Distributors Danazol api active pharmaceuticals ingredients Danazol manufacturers Side Effects bulk drugs raw material Danazol companies Side Effects Importers Danazol Danazol Exporters Danazol exporters FDA Danazol DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Danazol manufacturing pharmaceutical drugs pharmaceutical intermediates Danazol pharmaceutical chemicals pharmaceutical raw materials Danazol active pharmaceutical ingredients Danazol committee active pharmaceutical ingredients manufacturer Danazol Active Pharmaceutical Ingredients manufacturer Danazol exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Danazol, Danazol manufacturer India, Danazol product, Danazol products, Api preparation, Certificate of Analysis API manufacturer product, Danazol anti ulcer product, Certificate of Origin COA Danazol COS Danazol, pharmaceutical generic, pharmaceutical drug, medical, Danazol pharma healthcare, pharma patents, contract MSDS manufacturing Trader Danazol pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Danazol expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Danazol DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Danazol ingredients, api, HIV Danazol, tablets, capsules, syrup & protein Danazol powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Danazol gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Danazol WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

Danazol Img.















 

 







 

HOME >> API >> API List1 >> Danazol >> Precautions

Danazol  CAS Number 17230-88-5

PRECAUTIONS
Danazol CAS Number 17230-88-5

Use of Danazol in pregnancy is contraindicated. A sensitive test (e.g., beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally a nonhormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking Danazol, administration of the drug should be discontinued and the patient should be apprised of the potential risk to the fetus. Exposure to Danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received. (See PRECAUTIONS: Pregnancy, Teratogenic Effects.)

Thromboembolism, thrombotic and thrombophlebitic events including sagittal sinus thrombosis and life-threatening or fatal strokes have been reported.

Experience with long-term therapy with Danazol is limited. Peliosis hepatis and benign hepatic adenoma have been observed with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intra-abdominal hemorrhage. The physician therefore should be alert to this possibility. Attempts should be made to determine the lowest dose that will provide adequate protection. If the drug was begun at a time of exacerbation of hereditary angioneurotic edema due to trauma, stress or other cause, periodic attempts to decrease or withdraw therapy should be considered.

Danazol has been associated with several cases of benign intracranial hypertension also known as pseudotumor cerebri. Early signs and symptoms of benign intracranial hypertension include papilledema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilledema and, if present, the patients should be advised to discontinue Danazol immediately and be referred to a neurologist for further diagnosis and care.

A temporary alteration of lipoproteins in the form of decreased high density lipoproteins and possibly increased low density lipoproteins has been reported during Danazol therapy. These alterations may be marked, and prescribers should consider the potential impact on the risk of atherosclerosis and coronary artery disease in accordance with the potential benefit of the therapy to the patient.

Before initiating therapy of fibrocystic breast disease with Danazol, carcinoma of the breast should be excluded. However, nodularity, pain, tenderness due to fibrocystic breast disease may prevent recognition of underlying carcinoma before treatment is begun. Therefore, if any nodule persists or enlarges during treatment, carcinoma should be considered and ruled out.

Patients should be watched closely for signs of androgenic effects some of which may not be reversible even when drug administration is stopped.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE
SIDE EFFECTS
PRECAUTIONS >>
INTERACTION
PHARMALOGY
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Danazol

Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium

Clonazepam

Amitriptyline

Clopidogrel Bisulfate

Anastrozole

Danazol

Atomoxetine Hcl

Desloratadine

Balsalazide

Desmopressin Monoacetate

Bicalutamide

Divalproex Sodium

Budesonide

Dobutamine Hcl

Bupropion Hcl

Donepezil

Calcitonin

Dothiepin Hcl

Capecitabine

Entacapone

Carbamazepine

Eptifibatide

Carboplatin

Escitalopram HBr

Carisoprodol

Eszopiclone

Carvedilol

Finasteride

Cefuroxime Axetil

Flurbiprofen

Cisplatin

Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.